Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis

  • STATUS
    Recruiting
  • End date
    Jan 30, 2025
  • participants needed
    138
  • sponsor
    Erasmus Medical Center
Updated on 30 August 2021

Summary

This is a prospective, randomized, non-blinded, multi-center, non-inferiority trial designed to compare effectiveness and side-effects of methotrexate versus prednisolone as first-line therapy for pulmonary sarcoidosis..

Description

Sarcoidosis is a multisystem, granulomatous disorder, most commonly affecting the lungs. Symptom burden is high, and quality of life (QoL) and social participation are negatively affected. In patients with pulmonary sarcoidosis, treatment is recommended in case of significant symptoms and/or impaired or deteriorating lung function. Evidence-based treatment recommendations are limited, outdated and largely based on expert opinion.

Prednisone is currently the first-choice therapy in pulmonary sarcoidosis and leads to short-term improvement of lung function. Unfortunately, prednisone has major side-effects and is associated with impaired QoL. Methotrexate is presently considered second-line therapy, and appears to have fewer side-effects. The investigators hypothesize that first-line treatment with methotrexate is as effective as prednisone, with fewer side-effects and better QoL.

Details
Condition sarcoidosis, pulmonary, Pulmonary sarcoidosis
Treatment methotrexate, Prednisolone
Clinical Study IdentifierNCT04314193
SponsorErasmus Medical Center
Last Modified on30 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis of sarcoidosis according to the ATS/ERS/WASOG criteria, in case of absent histology a diagnosis of sarcoidosis can also be established in a multidisciplinary team meeting in a sarcoidosis expert center based on a highly suggestive clinical and radiological picture
Age 18 years
A pulmonary indication for treatment and parenchymal involvement on X-ray or CT-scan conducted within three months before inclusion (determined by the treating physician and conform current guidelines)
A forced vital capacity (FVC) of 90% of predicted, or a diffusion capacity of the lung for carbon monoxide (DLCO) 70% of predicted, or 5% FVC decline/10% DLCO decline in the past year. For pulmonary functions tests GLI reference values are used

Exclusion Criteria

Any condition or circumstance that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures
Previous immunosuppressive treatment for sarcoidosis
Use of systemic immunosuppressive therapy within the preceding three months for another disease than sarcoidosis
Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study treatment or within 90 days after the last dose in the randomized study phase. For males; planning to pro-create during the study or within 90 days after the last dose of the randomized study phase
Primary systemic treatment indication being an extra pulmonary location of sarcoidosis (e.g. cardiac of neurological)
Contra-indication for methotrexate or corticosteroids
severely impaired renal function (creatinine clearance <30 ml/min)
impaired hepatic function (serum bilirubin-value >5 mg/dl or 85,5 micromole/l)
bone marrow insufficiency with severe leukopenia, thrombocytopenia, or anaemia
severe acute or chronic infections, such as tuberculosis, HIV, parasitic infections or other immunodeficiency syndromes
mouth, stomach or duodenal ulcers
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note